Vir Biotechnology Reveals Phase 2 Data at AASLD The Liver Meeting® and in NEJM, Showing High Undetectable HDV RNA Rates and Positive Safety Profile for Tobevibart and Elebsiran Combination
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 09 2025
0mins
Should l Buy VIR?
Source: Newsfilter
SOLSTICE Trial Results: The SOLSTICE trial showed that 66% of participants with chronic hepatitis delta achieved undetectable HDV RNA after 48 weeks of treatment with the combination of tobevibart and elebsiran, with a favorable safety profile and no severe adverse events reported.
ECLIPSE Program: The ECLIPSE registrational program is underway to further evaluate the combination therapy, with topline data expected in the first quarter of 2027, aiming to address the unmet needs in chronic hepatitis delta treatment.
Significance of Findings: Achieving undetectable HDV RNA is crucial for better outcomes in chronic hepatitis delta patients, and the combination therapy has shown promising results in reducing hepatitis B surface antigen levels and normalizing ALT levels.
Regulatory Recognition: The combination therapy has received Breakthrough Therapy and Fast Track designations from the FDA, as well as Priority Medicines and orphan drug designations from the EMA, highlighting its potential as a significant treatment option.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VIR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VIR
Wall Street analysts forecast VIR stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.020
Low
12.00
Averages
15.60
High
24.00
Current: 9.020
Low
12.00
Averages
15.60
High
24.00
About VIR
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Investor Focus: Analysts' opinions are particularly crucial when considering the purchase of SMTC stock, as these insights may affect investor confidence and willingness to buy, directly impacting stock prices.
- Source of Updates: A complete view of all analyst rating changes, including upgrades and downgrades, can be found on our analyst ratings page, providing a comprehensive perspective to help investors make informed decisions.
- Market Dynamics Impact: The adjustments in analysts' ratings not only reflect views on company fundamentals but may also influence overall market sentiment, subsequently affecting trading volumes and price fluctuations of related stocks.
See More
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
Vir Biotechnology Announces Pricing of Public Offering
- Public Offering Pricing: Vir Biotechnology announced the pricing of 17.65 million shares at $8.50 each, expecting gross proceeds of $150 million, with the stock dropping 13.30% to $8.67 post-announcement, indicating a negative market reaction.
- Underwriter Selection: The offering is managed by Goldman Sachs, Leerink Partners, Evercore ISI, and Barclays, who also have a 30-day option to purchase an additional 2.65 million shares, reflecting cautious market sentiment regarding the company's future potential.
- Clinical Trial Progress: Vir's clinical-stage portfolio includes the Tobevibart + Elebsiran combination for chronic hepatitis Delta, with topline data expected between Q4 2026 and Q1 2027, showcasing the company's ongoing R&D efforts in the liver disease sector.
- Cash Flow Status: As of the end of 2025, Vir had $781.6 million in cash and cash equivalents, projected to fund operations into Q2 2028, demonstrating the company's robust financial management.
See More
Marriott Vacations Reports Strong Q4, Shares Surge
- Earnings Beat: Marriott Vacations reported an adjusted EPS of $1.86 for Q4, surpassing market expectations of $1.57, which highlights the company's strong profitability and boosts investor confidence.
- Sales Growth: The company's quarterly sales reached $1.323 billion, exceeding the anticipated $1.294 billion, indicating sustained competitiveness in the market and enhancing shareholder value.
- Stock Surge: In pre-market trading, Marriott Vacations shares jumped 12.7% to $65.34, reflecting market optimism about the company's future growth potential and likely attracting more investor interest.
- Positive Guidance: The company also issued FY26 adjusted EPS guidance above estimates, further solidifying its leadership position in the vacation industry and laying a strong foundation for future growth.
See More
Vir Biotechnology Prices Public Offering at $8.50 per Share
- Offering Size: Vir Biotechnology priced its public offering at approximately 17.65 million shares of common stock at $8.50 per share, expecting gross proceeds of about $150 million, indicating the company's ability to raise capital in the market.
- Underwriter Option: The underwriters have a 30-day option to purchase up to 2.65 million additional shares, which enhances market demand and liquidity for the stock.
- Market Reaction: Following the offering announcement, Vir Biotechnology's stock dropped 2.9% during after-market trading on Wednesday, reflecting cautious market sentiment that may impact short-term investor confidence.
- Future Outlook: The offering is expected to close on February 27, 2026, with proceeds aimed at supporting the company's $1.7 billion collaboration with Astellas, ensuring stable cash flow for the company in the coming years.
See More
Vir Biotechnology Prices Public Offering at $8.50 per Share
- Offering Size: Vir Biotechnology has priced its public offering at $8.50 per share for a total of 17,647,058 shares, expecting gross proceeds of $150 million, indicating strong market demand for its equity.
- Underwriter Selection: Goldman Sachs, Leerink Partners, Evercore ISI, and Barclays are acting as book-running managers for the offering, reflecting the company's high standards in selecting financial partners to ensure a smooth fundraising process.
- Additional Share Option: The company has granted underwriters a 30-day option to purchase an additional 2,647,058 shares, providing flexibility for further capital raising and potentially enhancing future financing capabilities.
- Compliance and Transparency: The offering is conducted under an SEC registration statement, ensuring compliance and transparency, which boosts investor confidence and may help the company attract more investments in the future.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Investor Focus: Analysts' opinions are particularly crucial when considering the purchase of SMTC stock, as these insights may affect investor confidence and willingness to buy, directly impacting stock prices.
- Source of Updates: A complete view of all analyst rating changes, including upgrades and downgrades, can be found on our analyst ratings page, providing a comprehensive perspective to help investors make informed decisions.
- Market Dynamics Impact: The adjustments in analysts' ratings not only reflect views on company fundamentals but may also influence overall market sentiment, subsequently affecting trading volumes and price fluctuations of related stocks.
See More
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
Vir Biotechnology Announces Pricing of Public Offering
- Public Offering Pricing: Vir Biotechnology announced the pricing of 17.65 million shares at $8.50 each, expecting gross proceeds of $150 million, with the stock dropping 13.30% to $8.67 post-announcement, indicating a negative market reaction.
- Underwriter Selection: The offering is managed by Goldman Sachs, Leerink Partners, Evercore ISI, and Barclays, who also have a 30-day option to purchase an additional 2.65 million shares, reflecting cautious market sentiment regarding the company's future potential.
- Clinical Trial Progress: Vir's clinical-stage portfolio includes the Tobevibart + Elebsiran combination for chronic hepatitis Delta, with topline data expected between Q4 2026 and Q1 2027, showcasing the company's ongoing R&D efforts in the liver disease sector.
- Cash Flow Status: As of the end of 2025, Vir had $781.6 million in cash and cash equivalents, projected to fund operations into Q2 2028, demonstrating the company's robust financial management.
See More
Marriott Vacations Reports Strong Q4, Shares Surge
- Earnings Beat: Marriott Vacations reported an adjusted EPS of $1.86 for Q4, surpassing market expectations of $1.57, which highlights the company's strong profitability and boosts investor confidence.
- Sales Growth: The company's quarterly sales reached $1.323 billion, exceeding the anticipated $1.294 billion, indicating sustained competitiveness in the market and enhancing shareholder value.
- Stock Surge: In pre-market trading, Marriott Vacations shares jumped 12.7% to $65.34, reflecting market optimism about the company's future growth potential and likely attracting more investor interest.
- Positive Guidance: The company also issued FY26 adjusted EPS guidance above estimates, further solidifying its leadership position in the vacation industry and laying a strong foundation for future growth.
See More
Vir Biotechnology Prices Public Offering at $8.50 per Share
- Offering Size: Vir Biotechnology priced its public offering at approximately 17.65 million shares of common stock at $8.50 per share, expecting gross proceeds of about $150 million, indicating the company's ability to raise capital in the market.
- Underwriter Option: The underwriters have a 30-day option to purchase up to 2.65 million additional shares, which enhances market demand and liquidity for the stock.
- Market Reaction: Following the offering announcement, Vir Biotechnology's stock dropped 2.9% during after-market trading on Wednesday, reflecting cautious market sentiment that may impact short-term investor confidence.
- Future Outlook: The offering is expected to close on February 27, 2026, with proceeds aimed at supporting the company's $1.7 billion collaboration with Astellas, ensuring stable cash flow for the company in the coming years.
See More
Vir Biotechnology Prices Public Offering at $8.50 per Share
- Offering Size: Vir Biotechnology has priced its public offering at $8.50 per share for a total of 17,647,058 shares, expecting gross proceeds of $150 million, indicating strong market demand for its equity.
- Underwriter Selection: Goldman Sachs, Leerink Partners, Evercore ISI, and Barclays are acting as book-running managers for the offering, reflecting the company's high standards in selecting financial partners to ensure a smooth fundraising process.
- Additional Share Option: The company has granted underwriters a 30-day option to purchase an additional 2,647,058 shares, providing flexibility for further capital raising and potentially enhancing future financing capabilities.
- Compliance and Transparency: The offering is conducted under an SEC registration statement, ensuring compliance and transparency, which boosts investor confidence and may help the company attract more investments in the future.
See More
